Gnosis by Lesaffre has unveiled a new business strategy which is the continued focus on microorganisms and biotransformation processes such as fermentation to cultivate nutritional actives, probiotics, and yeasts that will target five key market segments.
Gnosis by Lesaffre (Lille, France), a business unit of the Lesaffre Group, has unveiled a new business strategy at the core of which is the continued focus on microorganisms and biotransformation processes such as fermentation to cultivate nutritional actives, probiotics, and yeasts that will target five key market segments. These market segments are Wellness and Immune Health, Digestion and Gut Health, Mobility and Joint Health, Reproduction and Women’s Health, and Mood and Cognitive Health.
“The term ‘biotransformation’ may be unfamiliar to some in the industry, but it refers to fermentation and other natural processing methods that involve transforming compounds within a living system,” said Marc Philouze, general manager of Gnosis by Lesaffre, in a press release. “It describes exactly what we do. We use living microorganisms to transform compounds into usable nutritional actives.”
“In the past, we have focused solely on building awareness for our renowned ingredients, such as Quatrefolic and Lynside nutritional yeasts,” added global marketing director Philippe Caillat. “At the same time, we have been building our expertise and market leadership for our key market segments, so we are proud to bring those to the forefront of our brand strategy. We’re committed to always exploring the potential of biotransformation, which we believe is limitless. It’s truly an untapped, transformative resource that will help us develop natural, sustainable, and efficacious solutions for our partners.”